NCT03418441

Brief Summary

The Danish Study Group of Infections of the Brain is a collaboration between all departments of infectious diseases in Denmark. The investigators aim to monitor epidemiological trends in central nervous system (CNS) infections by a prospective registration of clinical characteristics and outcome of all adult (\>17 years of age) patients with community-acquired CNS infections diagnosed and/or treated at departments of infectious diseases in Denmark since 1st of January 2015.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,900

participants targeted

Target at P75+ for all trials

Timeline
44mo left

Started Jan 2015

Longer than P75 for all trials

Geographic Reach
1 country

8 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Jan 2015Jan 2030

Study Start

First participant enrolled

January 1, 2015

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

January 12, 2018

Completed
20 days until next milestone

First Posted

Study publicly available on registry

February 1, 2018

Completed
11.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2030

Last Updated

May 16, 2024

Status Verified

May 1, 2024

Enrollment Period

15 years

First QC Date

January 12, 2018

Last Update Submit

May 15, 2024

Conditions

Keywords

Nationwide prospective observational cohort studyEpidemiologyCentral Nervous System InfectionsMeningitisEncephalitisBrain abscessLyme diseaseNeuroborreliosisNeurosyphilisTertiary syphilis

Outcome Measures

Primary Outcomes (1)

  • Incidence

    Incidence of CNS infections in the adult population (\>17 years of age) in Denmark.

    One year

Secondary Outcomes (7)

  • Glasgow Outcome Scale score

    One month after end of treatment

  • Glasgow Outcome Scale score for viral meningitis

    30 days

  • Glasgow Outcome Scale score for bacterial meningitis

    30 days

  • Glasgow Outcome Scale score for encephalitis

    30 days

  • Glasgow Outcome Scale score for neurosyphilis

    2 weeks

  • +2 more secondary outcomes

Interventions

Prospective observational registration of clinical characteristics and outcome

Also known as: bacterial meningitis, viral meningitis, encephalitis, brain abscess, neuroborreliosis, neurosyphilis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients above 17 years of age are prospectively included in the DASGIB cohort by the principal investigator at each site if they have a clinical presentation suggestive of CNS infection (e.g. any combination of neck stiffness, fever, headache or altered mental status) and either (i) Positive CSF culture or positive bacterial/viral DNA-based analysis for (community-acquired) pathogens in the CSF or (ii) a positive blood culture and CSF leukocytes \>10/mL or (iii) CSF leukocytes \> 10/mL without any alternative diagnoses more likely to explain the patients' conditions. Exceptions apply for brain abscess, neurosyphilis and neuroborreliosis and exact definitions of included CNS infections are provided below. We exclude patients with hospital-acquired CNS infections as defined by the Centers for Disease Control and Prevention (Garner et al, Am J Infect Control, 1988), or an implanted neurosurgical device.

You may qualify if:

  • \- All patients have to have a clinical presentation consistent with non-bacterial meningitis (e.g. headache, neck stiffness, photo- or phonophobia, fever)
  • and
  • Cerebrospinal fluid leukocytes\>10 cells/ml
  • Patients with viral meningitis with undetermined pathogen have to have:
  • CSF leukocytes\> 10/mL and no other more probable diagnosis assessed by the local investigator.
  • In case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.
  • and
  • Proven bacterial aetiology (CSF or blood culture/DNA based technology or antigen tests)
  • Patients with bacterial meningitis in whom the bacteria cannot not be cultured or identified by DNA-based technologies have to have:
  • \- CSF leukocytes\> 10/mL and no other more probable diagnosis assessed by the local investigator.
  • In case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.

You may not qualify if:

  • \- We exclude cases of proven or suspected autoimmune encephalitis.
  • \- All patient have a clinical presentation consistent with brain abscess (e.g. headache, focal neurological deficit, mass lesion on cranial imaging)
  • and
  • \- Proven microbiological aetiology by culture/DNA-based technology from pus from brain abscess or blood or CSF
  • \- Aspiration of pus from the brain abscess
  • \- Response to antimicrobial treatment
  • \- Tumour ruled out
  • \- Tumour thought less probable than abscess on MRI using diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences.
  • \- A clinical presentation consistent with neuroborreliosis (e.g. radiculopathy)
  • and
  • \- CSF pleocytosis\>10 leukocytes/mL
  • and
  • \- Positive intrathecal B.burgdorferi antibody production index.
  • and either
  • \- Positive syphilis serology in serum combined with CSF leukocytes\>10/mL
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Department of Infectious Diseases, Aalborg University Hospital

Aalborg, 9000, Denmark

RECRUITING

Department of Infectious Diseases, Aarhus University Hospital Skejby

Aarhus, 8000, Denmark

RECRUITING

Department of Infectious Diseases, Rigshospitalet

Copenhagen, 2100, Denmark

RECRUITING

Herlev-Gentofte Hospital

Copenhagen, Denmark

RECRUITING

Department of Pulmonary and Infectious Diseases, Nordsjællands Hospital Hillerød

Hillerød, 3400, Denmark

RECRUITING

Department of Infectious Diseases, Hvidovre Hospital

Hvidovre, 2650, Denmark

RECRUITING

Department of Infectious Diseases, Odense University Hospital

Odense, 5100, Denmark

RECRUITING

Department of Pulmonary and Infectious Diseases, Sjællands University Hospital Roskilde

Roskilde, 4000, Denmark

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood and CSF samples are stored whenever available

MeSH Terms

Conditions

Central Nervous System InfectionsMeningitis, BacterialMeningitis, ViralMeningitis, AsepticEncephalitisBrain AbscessNeurosyphilisLyme DiseaseSyphilis, tertiaryMeningitis

Condition Hierarchy (Ancestors)

InfectionsCentral Nervous System DiseasesNervous System DiseasesCentral Nervous System Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesNeuroinflammatory DiseasesCentral Nervous System Viral DiseasesVirus DiseasesBrain DiseasesAbscessSuppurationSyphilisTreponemal InfectionsSpirochaetales InfectionsGram-Negative Bacterial InfectionsBorrelia InfectionsTick-Borne DiseasesVector Borne Diseases

Study Officials

  • Henrik Nielsen, Professor

    Aalborg University Hospital

    STUDY CHAIR

Central Study Contacts

Jacob Bodilsen, MD

CONTACT

Henrik Nielsen, Professor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

January 12, 2018

First Posted

February 1, 2018

Study Start

January 1, 2015

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2030

Last Updated

May 16, 2024

Record last verified: 2024-05

Locations